By browsing this website, you acknowledge the use of a simple identification cookie. It is not used for anything other than keeping track of your session from page to page. OK
0

Pleuropulmonary lesions, ergotamines and asbestos exposure

Bookmarks
Article

Hillerdal, Gunnar ; Rask-Andersen, Ann

Scandinavian Journal of Work, Environment and Health

2005

31

6

459-464

asbestos ; literature survey ; lung diseases ; pleural diseases

Sweden

Occupational safety and health

https://www.sjweh.fi/

English

Bibliogr.;Charts

"Objectives This study investigated the possibility of pleuropulmonary lesions, which can occur as rare but serious side effects of different ergot drugs, occurring more commonly in persons earlier exposed to asbestos.Methods All reports of pleuropulmonary side effects of the ergot drugs used in Sweden in the Swedish side effect registry from 1985 to 2003 were studied. In addition, the literature was reviewed.Results In the registry, 47 men and 3 women were found. Of the men, 24 were exposed to asbestos, and 2 denied such exposure; 2 of the 3 women were exposed. In the literature, 111 patients were found—32 had confirmed exposure and 15 denied it. For most of the patients, it was not possible to determine exposure.Conclusions Enough evidence exists to postulate that earlier asbestos exposure in combination with the intake of ergot drugs can cause pleuropulmonary lesions."(Authors' abstract)

Digital



Bookmarks